These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 33482345)

  • 21. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
    Rizzo A; Palmiotti G
    Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapy Approaches for Breast Cancer Patients in 2023.
    Emens LA; Loi S
    Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
    Gonzalez-Ericsson PI; Wulfkhule JD; Gallagher RI; Sun X; Axelrod ML; Sheng Q; Luo N; Gomez H; Sanchez V; Sanders M; Pusztai L; Petricoin E; Blenman KRM; Balko JM;
    Clin Cancer Res; 2021 Oct; 27(19):5299-5306. PubMed ID: 34315723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
    J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
    Front Oncol; 2021; 11():657634. PubMed ID: 34912699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials of immunotherapy in triple-negative breast cancer.
    Howard FM; Pearson AT; Nanda R
    Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.
    Ali MA; Aiman W; Shah SS; Hussain M; Kashyap R
    Crit Rev Oncol Hematol; 2021 Jan; 157():103197. PubMed ID: 33309890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
    Deng H; Wang L; Wang N; Zhang K; Zhao Y; Qiu P; Qi X; Zhang D; Xu F; Liu J
    BMC Cancer; 2023 Jan; 23(1):29. PubMed ID: 36611131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials.
    Petrelli F; Tomasello G; Parati MC; Ghidini A; Ghidini M; Borgonovo K; Cabiddu M; Ghilardi M; Reduzzi R; Gambini D; Zaniboni A; Faustinelli G; Garrone O
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399628
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in triple negative breast cancer: the immunotherapy era.
    Marra A; Viale G; Curigliano G
    BMC Med; 2019 May; 17(1):90. PubMed ID: 31068190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
    BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
    Sinn BV; Loibl S; Hanusch CA; Zahm DM; Sinn HP; Untch M; Weber K; Karn T; Becker C; Marmé F; Schmitt WD; Müller V; Schem C; Treue D; Stickeler E; Klauschen F; Burchardi N; Furlanetto J; van Mackelenbergh M; Fasching PA; Schneeweiss A; Denkert C
    Clin Cancer Res; 2021 May; 27(9):2584-2591. PubMed ID: 33593886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.